Circulating vascular endothelial growth factor in the normo- and/or microalbuminuric patients with type 2 diabetes mellitus.
Relationship between serum vascular endothelial growth factor (VEGF) level and parameters of endothelial injury and/or dysfunction in patients with diabetes mellitus type 2 with or without microalbuminuria was investigated. Eighty-four diabetic patients were divided in two subgroups (42 each): normoalbuminuric (NAU) and microalbuminuric (MAU). Forty-two blood donors were in control group. Serum VEGF and plasma von Willebrand factor, soluble thrombomodulin, plasminogen activator inhibitor 1, thrombin-activatable fibrinolysis inhibitor (TAFI) and tissue plasminogen activator (t-PA) were measured using enzyme-linked immunosorbent assay in all subjects. VEGF was significantly higher in NAU compared to controls. The difference between MAU and controls was not statistically significant, but there was a trend toward significance. Only TAFI correlated with VEGF in MAU. An observed significant increase of serum VEGF level already in NAU suggests that serum VEGF could be a sensitive predictor of endothelial dysfunction in type 2 diabetes.
National Center of Hemostasis and Thrombosis, Jessenius Faculty of Medicine, Comenius University, Kollárova 2, 036 59, Martin, Slovakia. kubisz@jfmed.uniba.sk
Peter
P
Kubisz
Peter
P
Chudý
Ján
J
Stasko
Peter
P
Galajda
Pavol
P
Hollý
Robert
R
Vysehradský
Marián
M
Mokán
D000368:Aged; D000419:Albuminuria / Q000097:blood / Q000453:epidemiology*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D015992:Body Mass Index; D025901:Carboxypeptidase B2 / Q000097:blood; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D005919:Glomerular Filtration Rate; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011237:Predictive Value of Tests; D010959:Tissue Plasminogen Activator / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D000959:Antihypertensive Agents; D015415:Biomarkers; D025901:Carboxypeptidase B2; D003404:Creatinine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator; D042461:Vascular Endothelial Growth Factor A